TY - JOUR
T1 - Risks and benefits of hormone therapy after menopause for cognitive decline and dementia
T2 - A conceptual review
AU - Rocca, Walter A.
AU - Kantarci, Kejal
AU - Faubion, Stephanie S.
N1 - Publisher Copyright:
© 2023
PY - 2024/6
Y1 - 2024/6
N2 - Objective: The effects on the brain of hormone therapy after the onset of menopause remain uncertain. The effects may be beneficial, neutral, or harmful. We provide a conceptual review of the evidence. Methods: We 1) provide a brief history of the evidence, 2) discuss some of the interpretations of the evidence, 3) discuss the importance of age at menopause, type of menopause, and presence of vasomotor symptoms, and 4) provide some clinical recommendations. Results: The evidence and the beliefs about hormone therapy and dementia have changed over the last 30 years or more. Five recent observation studies suggested that hormone therapy is associated with an increased risk of dementia, and the association appears not to change with the timing of initiation of therapy. These harmful associations may be explained by a causal effect of hormone therapy on the brain or by several confounding mechanisms. We suggest that the use of hormone therapy should be customized for different subgroups of women. It may be important to subgroup women based on age at onset of menopause, type of menopause, and presence or absence of vasomotor symptoms. In addition, the effects may vary by type, dose, route, and duration of administration of estrogens and by the concurrent use of progestogens. Discussion: The relation of hormone therapy with the risk of dementia is complex. Hormone therapy may have beneficial, neutral, or harmful effects on the brain. Hormone therapy should be guided by the clinical characteristics of the women being treated.
AB - Objective: The effects on the brain of hormone therapy after the onset of menopause remain uncertain. The effects may be beneficial, neutral, or harmful. We provide a conceptual review of the evidence. Methods: We 1) provide a brief history of the evidence, 2) discuss some of the interpretations of the evidence, 3) discuss the importance of age at menopause, type of menopause, and presence of vasomotor symptoms, and 4) provide some clinical recommendations. Results: The evidence and the beliefs about hormone therapy and dementia have changed over the last 30 years or more. Five recent observation studies suggested that hormone therapy is associated with an increased risk of dementia, and the association appears not to change with the timing of initiation of therapy. These harmful associations may be explained by a causal effect of hormone therapy on the brain or by several confounding mechanisms. We suggest that the use of hormone therapy should be customized for different subgroups of women. It may be important to subgroup women based on age at onset of menopause, type of menopause, and presence or absence of vasomotor symptoms. In addition, the effects may vary by type, dose, route, and duration of administration of estrogens and by the concurrent use of progestogens. Discussion: The relation of hormone therapy with the risk of dementia is complex. Hormone therapy may have beneficial, neutral, or harmful effects on the brain. Hormone therapy should be guided by the clinical characteristics of the women being treated.
KW - Age at menopause
KW - Dementia
KW - Hormone therapy
KW - Type of menopause
KW - Vasomotor symptoms
UR - http://www.scopus.com/inward/record.url?scp=85190819013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190819013&partnerID=8YFLogxK
U2 - 10.1016/j.maturitas.2024.108003
DO - 10.1016/j.maturitas.2024.108003
M3 - Review article
C2 - 38649310
AN - SCOPUS:85190819013
SN - 0378-5122
VL - 184
JO - Maturitas
JF - Maturitas
M1 - 108003
ER -